Internal Medicine, Rheumatology · Anchorage, AK
NPI
1881700334
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
3801 Lake Otis Pkwy Ste 300
Anchorage, AK, 99508
Phone (907) 562-2277
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.1M
253,127 services
Medicare patients, 2024
1,188
Average age 73
Drug cost, 2024
$4.0M
2,281 prescriptions
Company payments, 2025
$134K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John K Botson was code J3111 (injection, romosozumab-aqqg, 1 mg), 93,870 times for 78 patients. In total John K Botson billed 253,127 services in 116 codes, and Medicare paid $5.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 93,870 | 78 | $8.52 | $800K |
| J3262 Injection, tocilizumab, 1 mg | Office | 57,744 | 18 | $4.72 | $272K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 15,093 | 49 | $24.74 | $373K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 10,600 | 14 | $9.06 | $96K |
| J0897 Injection, denosumab, 1 mg | Office | 8,700 | 100 | $20.34 | $177K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,000 | 12 | $33.90 | $271K |
| J9312 Injection, rituximab, 10 mg | Office | 3,960 | 15 | $61.26 | $243K |
| J0638 Injection, canakinumab, 1 mg | Office | 2,250 | 13 | $93.61 | $211K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,569 | 19 | $0.23 | $354 |
| 96372 Injection Administration | Office | 978 | 179 | $12.94 | $13K |
| 77080 Standard X-ray | Office | 719 | 717 | $42.79 | $31K |
| 96413 Chemotherapy Administration | Office | 665 | 118 | $105.79 | $70K |
| J2507 Injection, pegloticase, 1 mg | Office | 648 | 13 | $2,647.78 | $1.7M |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 601 | 63 | $0.76 | $456 |
| 36415 Venipuncture Blood Collection | Office | 523 | 204 | $8.47 | $4,429 |
By year: 2022 $2.4M for 140,072 services; 2023 $5.1M for 186,377 services; 2024 $5.1M for 253,127 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 523 | 204 | $8.47 | $4,429 |
| 80053 Clinical Chemistry | 252 | 129 | $10.25 | $2,584 |
| 85025 Blood Count | 237 | 125 | $7.55 | $1,790 |
| 86140 Clinical Chemistry | 221 | 121 | $5.04 | $1,114 |
| 85651 Clinical Chemistry | 214 | 117 | $4.18 | $895 |
| 84550 Clinical Chemistry | 126 | 34 | $4.32 | $544 |
| 82306 Clinical Chemistry | 20 | 20 | $29.01 | $580 |
| 81003 Clinical Chemistry | 16 | 14 | $2.20 | $35.2 |
Medicare prescription drug claims, 2024
In 2024, the drug John K Botson prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 304 prescriptions and refills. In total John K Botson wrote 2,281 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 304 | 738 | 82 | $13K |
| Prednisone Generic | 231 | 325 | 78 | $1,555 |
| Hydroxychloroquine Sulfate Generic | 217 | 580 | 61 | $17K |
| Allopurinol Generic | 126 | 276 | 36 | $2,245 |
| Meloxicam Generic | 97 | 199 | 31 | $719 |
| Gabapentin Generic | 88 | 180 | 23 | $925 |
| Xeljanz Xr Tofacitinib Citrate | 79 | 131 | 11 | $749K |
| Leflunomide Generic | 76 | 181 | 16 | $7,082 |
| Febuxostat Generic | 61 | 113 | 13 | $3,308 |
| Rinvoq Upadacitinib | 55 | 91 | Under 11 | $566K |
| Tramadol Hcl Generic | 48 | 48 | 12 | $800 |
| Azathioprine Generic | 47 | 114 | 12 | $3,141 |
| Celecoxib Generic | 45 | 111 | 19 | $2,143 |
| Diclofenac Sodium Generic | 34 | 60 | 20 | $5,256 |
| Humira(Cf) Adalimumab | 32 | 43 | Under 11 | $375K |
Brand drugs: 441 claims; generic drugs: 1,840 claims; opioid claims: 69.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John K Botson $134K ($129K in general payments such as food, travel and fees and $4,864 for research) from 16 companies. The largest payer was Amgen Inc. with $83K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 60 | $83K |
| ANI Pharmaceuticals, Inc. ANIP | 26 | $22K |
| Abbvie Inc. ABBV | 25 | $15K |
| Sobi, Inc SOBI.ST | 10 | $8,843 |
| Eli Lilly and Company LLY | 1 | $2,725 |
| Pfizer Inc. PFE | 3 | $1,347 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $943 |
| Janssen Biotech, Inc. JNJ | 5 | $205 |
| Mallinckrodt Hospital Products Inc. | 3 | $165 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $159 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.